Physician
Oncology
Dr. Brendan D. Curti, MD
|
|
Give Review
Brendan Curti works in the field of Oncology. He went to medical school at Georgetown University School of Medicine. Georgetown University School of Medicine has a rank of 49 in research and a 84 in primary care He has 1 awards "CMS Meaningful Use Stage 1 Certification". Brendan Curti is a published doctor. He published 50 publications, including: 'Alterations in T cell receptor and signal transduction molecules in melanoma patients.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.
- Clinical deployment of antibodies for treatment of Melanoma.
- The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma.
- Clinical impact of sentinel lymph node biopsy in patients with thick (>4 mm) Melanomas.
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients.
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- Radiation and immunotherapy: Renewed allies in the war on Cancer.
- Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.
- Defining a functionally distinct subset of human memory CD4(+) T Cells that are CD25(POS) and FOXP3(NEG).
- Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell Carcinoma.
- Sunitinib efficacy against advanced renal cell Carcinoma.
- Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell Carcinoma.
- Sunitinib in patients with metastatic renal cell Carcinoma.
- Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from Melanoma.
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal Cancer in a Community Hospital Biotherapy Program.
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell Carcinoma: a phase 1/2 study.
- A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic Melanoma in the United States.
- A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell Carcinoma: a Cytokine Working Group (CWG) study.
- Adoptive immunotherapy.
- The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.
- Interleukin 1 alpha increases serum leptin concentrations in humans.
- Adoptive transfer of anti-CD3-activated CD4+ T Cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor...
- Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in Cancer patients.
- Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy Cell leukemia.
- Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing ...
- Interstitial pressure of subcutaneous nodules in melanoma and Lymphoma patients: changes during treatment.
- Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes.
- Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced Cancer.
- Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-Cancer, renal-cell carcinoma and malignant-melanoma.
- Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced Cancer.
- Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T Cells: results from a phase I trial in c...
- Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent Lymphoma: results of a phase II study.
- Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic Melanoma.
- The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced Malignancies.
- A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell Carcinoma.
- A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal Cell...
- A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic Melanoma.
- Alterations in T cell receptor and signal transDuction molecules in melanoma patients.
- Treatment of Cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
- Signaling through OX40 enhances antitumor immunity.
- Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell Carcinoma sorafenib expanded access program.
- Safety and efficacy results of the advanced renal cell Carcinoma sorafenib expanded access program in North America.
- Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.
- Characterization of the class I-restricted gp100 Melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
- Temozolomide, thalidomide, and whole Brain radiation therapy for patients with Brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
- Science gone translational: the OX40 agonist story.
- gp100 peptide vaccine and interleukin-2 in patients with advanced Melanoma.
- Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.
- Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell Carcinoma.
Schools
Georgetown Univ Sch Of Med
Ms Hershey Med Center
Georgetown University Hospital
Nci
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Georgetown University Hospital -
Penn State University -
Georgetown University School of Medicine
Hospital
-
Providence Portland Medical Center
Drug Facts
| NPI NUMBER | 1861494650 | |
| NPPES Provider LastName | CURTI | |
| NPPES Provider FirstName | BRENDAN | |
| NPPES Provider ZIPCode | 972132933 | |
| NPPES Provider State | OR | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 201.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 5.47 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861494650 |
| Last Name Of The Provider | CURTI |
| First Name Of The Provider | BRENDAN |
| View All |
Similar Doctors
|
|
Dr. Keith J. Stelzer, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Phuong T. Doan, MD |
|
|
Dr. Kim J. Burchiel, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Tomasz M. Beer, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Tibor J. Kovacsovics, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Theresa S. Devere, MD |
|
|
Mary E. Gramling, PT |